Q1 Earnings Forecast for Genmab A/S Issued By HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Equities researchers at HC Wainwright dropped their Q1 2026 earnings per share estimates for Genmab A/S in a report released on Wednesday, February 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.15 for the quarter, down from their prior estimate of $0.27. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S’s Q2 2026 earnings at $0.53 EPS, Q3 2026 earnings at $0.53 EPS, Q4 2026 earnings at $0.54 EPS and FY2026 earnings at $1.75 EPS.

Other equities research analysts also recently issued reports about the stock. Truist Financial reissued a “buy” rating and issued a $48.00 price objective (down from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Zacks Research cut Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Jefferies Financial Group began coverage on Genmab A/S in a research report on Tuesday. They set a “buy” rating and a $41.50 price objective for the company. Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Finally, Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $41.30.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $28.90 on Friday. The business has a 50-day simple moving average of $32.19 and a 200-day simple moving average of $29.87. The company has a market cap of $18.56 billion, a PE ratio of 18.65, a P/E/G ratio of 17.12 and a beta of 0.90. Genmab A/S has a one year low of $17.24 and a one year high of $35.43. The company has a debt-to-equity ratio of 0.86, a quick ratio of 6.01 and a current ratio of 2.02.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.46 by ($0.41). The company had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GMAB. CIBC Private Wealth Group LLC grew its position in shares of Genmab A/S by 291.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after acquiring an additional 616 shares during the last quarter. Osaic Holdings Inc. boosted its stake in Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the period. CWM LLC grew its position in Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after purchasing an additional 603 shares during the last quarter. NewEdge Advisors LLC increased its position in Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after acquiring an additional 1,143 shares during the period. Finally, Brown Brothers Harriman & Co. lifted its position in Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after acquiring an additional 780 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S News Summary

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright raised its price target to $40 and reiterated a “buy” rating, signaling meaningful upside vs. the current price and offering support for the stock. HC Wainwright raises target
• Positive Sentiment: Jefferies initiated coverage on Genmab, which typically increases visibility and trading interest from institutional investors. Jefferies Initiates Coverage
• Positive Sentiment: Morgan Stanley also began coverage, adding further analyst attention and potential buy-side interest. Morgan Stanley Begins Coverage
• Positive Sentiment: Consensus brokerage coverage across firms is a “Moderate Buy,” which may cushion downside and attract buyers at current levels. Consensus Moderate Buy
• Neutral Sentiment: Genmab summoned its Annual General Meeting for March 19, 2026 — routine corporate governance news without direct near-term earnings impact. AGM Notice
• Neutral Sentiment: A Benzinga roundup and other analyst summaries aggregate views from four analysts; useful for context but not a single catalyst. Analyst Outlook Roundup
• Neutral Sentiment: Short-interest reporting shows anomalous/zero values (data appears inconsistent), so it offers no clear read on immediate shorting pressure.
• Negative Sentiment: Q4 EPS missed estimates — reported ~$0.40 vs. ~$0.46 consensus — which is the primary near-term negative driver pressuring the stock despite revenue roughly meeting expectations. Q4 2025 Earnings Call Transcript

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.